Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection

References

• McInnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med Overseas Ed20113652322052219
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDMcInnesIBRheumatoid arthritisLancet2016388100552023203827156434
   PubMed Web of Science ®Google Scholar
• SmolenJSBreedveldFCBurmesterGRTreating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnn Rheum Dis201675131525969430
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDRedlichKThe pathogenesis of rheumatoid arthritis: new insights from old clinical data?Nat Rev Rheumatol20128423524322410633
   PubMed Web of Science ®Google Scholar
• McInnesIBBuckleyCDIsaacsJDCytokines in rheumatoid arthritis – shaping the immunological landscapeNat Rev Rheumatol2016121636826656659
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBijlsmaJEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnn Rheum Dis201776696097728264816
   PubMed Web of Science ®Google Scholar
• SinghJASaagKGBridgesSLAmerican College of Rheumatology guideline for the treatment of rheumatoid arthritisArthritis Rheumatol2016681126
   PubMed Web of Science ®Google Scholar
• NamJLTakase-MinegishiKRamiroSEfficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis20177661113113628283512
   PubMed Web of Science ®Google Scholar
• MarchesoniAZaccaraEGorlaRTNF-α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practiceAnn N Y Acad Sci20091173183784619758236
   PubMed Web of Science ®Google Scholar
• FavalliEGPregnolatoFBiggioggeroMTwelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registryArthritis Care Res2016684432439
   PubMed Web of Science ®Google Scholar
• FavalliEGRaimondoMGBeccioliniACrottiCBiggioggeroMCaporaliRThe management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectivesAutoimmun Rev201716121185119529037899
   PubMed Web of Science ®Google Scholar
• ChoyEUnderstanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritisRheumatology201251Suppl 5v3v1122718924
   PubMed Web of Science ®Google Scholar
• DayerJ-MChoyETherapeutic targets in rheumatoid arthritis: the interleukin-6 receptorRheumatology2010491152419854855
   PubMed Web of Science ®Google Scholar
• RaimondoMGBiggioggeroMCrottiCBeccioliniAFavalliEGProfile of sarilumab and its potential in the treatment of rheumatoid arthritisDrug Des Devel Ther20171115931603
   PubMed Web of Science ®Google Scholar
• Rose-JohnSWinthropKCalabreseLThe role of IL-6 in host defence against infections: immunobiology and clinical implicationsNat Rev Rheumatol201713739940928615731
   PubMed Web of Science ®Google Scholar
• WolfJRose-JohnSGarbersCInterleukin-6 and its receptors: a highly regulated and dynamic systemCytokine2014701112024986424
   PubMed Web of Science ®Google Scholar
• JohnsonDEO’KeefeRAGrandisJRTargeting the IL-6/JAK/STAT3 signalling axis in cancerNat Rev Clin Oncol201815423424829405201
   PubMed Web of Science ®Google Scholar
• AnayaJ-MDuarte-ReyCSarmiento-MonroyJCBardeyDCastiblancoJRojas-VillarragaAPersonalized medicine. Closing the gap between knowledge and clinical practiceAutoimmun Rev201615883384227302209
   PubMed Web of Science ®Google Scholar
• SelmiCKonESantisMDHow advances in personalized medicine will change rheumatologyPer Med2018152757829714121
   PubMed Web of Science ®Google Scholar
• KielyPDWBiologic efficacy optimization – a step towards personalized medicineRheumatology201655578078826424837
   PubMed Web of Science ®Google Scholar
• CantiniFNiccoliLNanniniCTailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritisSemin Arthritis Rheum201645551953226607440
   PubMed Web of Science ®Google Scholar
• CantiniFNiccoliLNanniniCSecond-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisSemin Arthritis Rheum201747218319228413099
   PubMed Web of Science ®Google Scholar
• FonsecaJESantosMJCanhãoHChoyEInterleukin-6 as a key player in systemic inflammation and joint destructionAutoimmun Rev20098753854219189867
   PubMed Web of Science ®Google Scholar
• GossecLSteinbergGRouanetSCombeBFatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS StudyClin Exp Rheumatol201533566467026344671
   PubMed Web of Science ®Google Scholar
• SongS-NJTomosugiNKawabataHIshikawaTNishikawaTYoshizakiKDown-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman diseaseBlood2010116183627363420644113
   PubMed Web of Science ®Google Scholar
• Abdel MeguidMHHamadYHSwilamRSBarakatMSRelation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damageRheumatol Int201333369770322531887
   PubMed Web of Science ®Google Scholar
• ChoyEHSCalabreseLHNeuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritisRheumatology201857111885189529186541
   PubMed Web of Science ®Google Scholar
• FèveBBastardJ-PThe role of interleukins in insulin resistance and type 2 diabetes mellitusNat Rev Endocrinol20095630531119399017
   PubMed Web of Science ®Google Scholar
• DaneshJKaptogeSMannAGLong-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic reviewPLoS Med200854e7818399716
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNStampferMJHennekensCHPlasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy menCirculation2000101151767177210769275
   PubMed Web of Science ®Google Scholar
• GabayCEmeryPvan VollenhovenRTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet201338198771541155023515142
   PubMed Web of Science ®Google Scholar
• BurmesterGRLinYPatelREfficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trialAnn Rheum Dis201776584084727856432
   PubMed Web of Science ®Google Scholar
• KishimotoTIL-6: from laboratory to bedsideClin Rev Allergy Immunol200528317718616129902
   PubMed Web of Science ®Google Scholar
• TanakaTKishimotoTThe biology and medical implications of interleukin-6Cancer Immunol Res20142428829424764575
   PubMed Web of Science ®Google Scholar
• MuraguchiAHiranoTTangBThe essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cellsJ Exp Med198816723323443258006
   PubMed Web of Science ®Google Scholar
• JegoGBatailleRPellat-DeceunynckCInterleukin-6 is a growth factor for nonmalignant human plasmablastsBlood20019761817182211238125
   PubMed Web of Science ®Google Scholar
• KimuraAKishimotoTIL-6: regulator of Treg/Th17 balanceEur J Immunol20104071830183520583029
   PubMed Web of Science ®Google Scholar
• BettelliECarrierYGaoWReciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature2006441709023523816648838
   PubMed Web of Science ®Google Scholar
• VeldhoenMHockingRJAtkinsCJLocksleyRMStockingerBTGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T CellsImmunity200624217918916473830
   PubMed Web of Science ®Google Scholar
• CastellJVGómez-LechónMJDavidMFabraRTrullenqueRHeinrichPCAcute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6Hepatology1990125117911861699862
   PubMed Web of Science ®Google Scholar
• HeinrichPCCastellJVAndusTInterleukin-6 and the acute phase responseBiochem J199026536216361689567
   PubMed Web of Science ®Google Scholar
• BartokBFiresteinGSFibroblast-like synoviocytes: key effector cells in rheumatoid arthritisImmunol Rev2010233123325520193003
   PubMed Web of Science ®Google Scholar
• GabayCInterleukin-6 and chronic inflammationArthritis Res Ther20068Suppl 2S3
   PubMed Web of Science ®Google Scholar
• HeinGEKöhlerMOelznerPSteinGFrankeSThe advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritisRheumatol Int200526213714115580352
   PubMed Web of Science ®Google Scholar
• AbeHSakaiTAndoWSynovial joint fluid cytokine levels in hip diseaseRheumatology201453116517224136066
   PubMed Web of Science ®Google Scholar
• DesgeorgesAGabayCSilacciPConcentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluidJ Rheumatol1997248151015169263143
   PubMed Web of Science ®Google Scholar
• DasguptaBCorkillMKirkhamBGibsonTPanayiGSerial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritisJ Rheumatol199219122251556695
   PubMed Web of Science ®Google Scholar
• KishimotoTInterleukin-6: from basic science to medicine – 40 years in immunologyAnnu Rev Immunol200523112115771564
   PubMed Web of Science ®Google Scholar
• LallyFSmithEFilerAA novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synoviumArthritis Rheum200552113460346916255036
   PubMed Web of Science ®Google Scholar
• KaplanskiGMarinVMontero-JulianFMantovaniAFarnarierCIL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammationTrends Immunol2003241252912495721
   PubMed Web of Science ®Google Scholar
• HashizumeMHayakawaNMiharaMIL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17Rheumatology200847111635164018786965
   PubMed Web of Science ®Google Scholar
• Rose-JohnSIL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6Int J Biol Sci2012891237124723136552
   PubMed Web of Science ®Google Scholar
• Rose-JohnSSchellerJElsonGJonesSAInterleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancerJ Leukoc Biol200680222723616707558
   PubMed Web of Science ®Google Scholar
• MärzPChengJ-GGadientRASympathetic neurons can produce and respond to interleukin 6Proc Natl Acad Sci U S A1998956325132569501249
   PubMed Web of Science ®Google Scholar
• ObrejaOBiasioWAndratschMFast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neuronsBrain200512871634164115817518
   PubMed Web of Science ®Google Scholar
• MastorakosGChrousosGPWeberJSRecombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humansJ Clin Endocrinol Metab1993776169016948263159
   PubMed Web of Science ®Google Scholar
• EijsboutsAMvan den HoogenFHLaanRFHermusARSweepCGvan de PutteLBHypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritisClin Exp Rheumatol200523565866416173242
   PubMed Web of Science ®Google Scholar
• JonesSARichardsPJSchellerJRose-JohnSIL-6 transsignaling: the in vivo consequencesJ Interferon Cytokine Res200525524125315871661
   PubMed Web of Science ®Google Scholar
• TanakaTNarazakiMKishimotoTIL-6 in inflammation, immunity, and diseaseCold Spring Harb Perspect Biol2014610a01629525190079
   PubMed Web of Science ®Google Scholar
• NemethETuttleMSPowelsonJHepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalizationScience200430657042090209315514116
   PubMed Web of Science ®Google Scholar
• WeissGSchettGAnaemia in inflammatory rheumatic diseasesNat Rev Rheumatol20139420521523147894
   PubMed Web of Science ®Google Scholar
• ChoyEGaneshalingamKSembAGSzekaneczZNurmohamedMCardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentRheumatology201453122143215424907149
   PubMed Web of Science ®Google Scholar
• RidkerPMHennekensCHBuringJERifaiNC-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in womenN Engl J Med Overseas Ed200034212836843
   PubMed Web of Science ®Google Scholar
• Roche Registration LtdRoActemra 20 mg/ml Concentrate for Solution for InfusionWelwynn Garden CityRoche Registration Ltd2014
   Google Scholar
• Genentech IncActemra (tocilizumab) Injection for Intravenous InfusionSouth San FranciscoGenentech, Inc.2017
   Google Scholar
• KremerJMBlancoRBrzoskoMTocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structuArthritis Rheum201163360962121360490
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis20106901889619297346
   PubMed Web of Science ®Google Scholar
• EmeryPKeystoneETonyHPIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnn Rheum Dis200867111516152318625622
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialLancet2008371961798799718358926
   PubMed Web of Science ®Google Scholar
• KivitzAOlechEBorofskyMSubcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritisArthritis Care Res2014661116531661
   PubMed Web of Science ®Google Scholar
• BurmesterGRRubbert-RothACantagrelAA randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Ann Rheum Dis2014731697423904473
   PubMed Web of Science ®Google Scholar
• GabayCRiekMHetlandMLEffectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative studyAnn Rheum Dis20167571336134226374404
   PubMed Web of Science ®Google Scholar
• LauperKNordströmDCPavelkaKComparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationAnn Rheum Dis20187791276128229730637
   PubMed Web of Science ®Google Scholar
• IannoneFFerraccioliGSinigagliaLReal-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEAClin Rheumatol201837231532128980085
   PubMed Web of Science ®Google Scholar
• IannazzoSBenucciMFavalliEGTocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian settingClin Exp Rheumatol201836347948529352843
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMiyasakaNTreatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trialArthritis Rheum20045061761176915188351
   PubMed Web of Science ®Google Scholar
• YaziciYCurtisJRInceAEfficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE studyAnn Rheum Dis201271219820521949007
   PubMed Web of Science ®Google Scholar
• SinghJABegSLopez-OlivoMATocilizumab for rheumatoid arthritis: a Cochrane systematic reviewJ Rheumatol2011381102020952462
   PubMed Web of Science ®Google Scholar
• BergmanGJDHochbergMCBoersMWintfeldNKielhornAJansenJPIndirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugsSemin Arthritis Rheum201039642544120223500
   PubMed Web of Science ®Google Scholar
• BykerkVPÖstörAJKAlvaro-GraciaJTocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practiceAnn Rheum Dis201271121950195422615456
   PubMed Web of Science ®Google Scholar
• Iking-KonertCvon HinüberURichterCROUTINE – a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in GermanyRheumatology201655462463526515959
   PubMed Web of Science ®Google Scholar
• BalsaATovar BeltránJVCáliz CálizRPatterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE studyRheumatol Int20153591525153425773655
   PubMed Web of Science ®Google Scholar
• KiharaMDaviesRKearsley-FleetLUse and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritisClin Rheumatol201736224125027913894
   PubMed Web of Science ®Google Scholar
• BackhausMKaufmannJRichterCComparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practiceClin Rheumatol201534467368125630309
   PubMed Web of Science ®Google Scholar
• ChoyEHBernasconiCAassiMMolinaJFEpisOMTreatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational StudyArthritis Care Res2017691014841494
   PubMed Web of Science ®Google Scholar
• DennisGHolwegCTJKummerfeldSKSynovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeuticsArthritis Res Ther2014162R9025167216
   PubMed Web of Science ®Google Scholar
• GremeseECarlettoAPadovanMObesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicineArthritis Care Res201365194100
   PubMed Web of Science ®Google Scholar
• HyrichKLWatsonKDSilmanAJSymmonsDPThe BSR Biologics RegisterPredictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterRheumatology200645121558156516705046
   PubMed Web of Science ®Google Scholar
• SokoloveJSchiffMFleischmannRImpact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trialAnn Rheum Dis201675470971426359449
   PubMed Web of Science ®Google Scholar
• IsaacsJDCohenSBEmeryPEffect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysisAnn Rheum Dis201372332933622689315
   PubMed Web of Science ®Google Scholar
• Martin-MolaEBalsaAGarcía-VicunaRAnti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a reviewRheumatol Int20163681043106327271502
   PubMed Web of Science ®Google Scholar
• PersY-MGodfrin-ValnetMLambertJResponse to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patientJ Rheumatol201542458058425641885
   PubMed Web of Science ®Google Scholar
• TheanderEProvenAFallangASvelanderLTrollmoTFRI0163 smoking status does not seem to affect tocilizumab efficacy in RA patientsAnn Rheum Dis201574Suppl 2482
   Web of Science ®Google Scholar
• NarváezJMagallaresBDíaz TornéCPredictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practiceSemin Arthritis Rheum201645438639026254548
   PubMed Web of Science ®Google Scholar
• WangJDevenportJLowJMYuDHitrayaERelationship between baseline and early changes in c-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritisArthritis Care Res2016686882885
   PubMed Web of Science ®Google Scholar
• Diaz-TorneCOrtizMDAMoyaPThe combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumabSemin Arthritis Rheum201847675776429157669
   PubMed Web of Science ®Google Scholar
• NakagawaJKoyamaYKawakamiAA novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational studyArthritis Res Ther201719118528800780
   PubMed Web of Science ®Google Scholar
• GiacomelliRAfeltraAAlunnoAInternational consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?Autoimmun Rev201716991192428705780
   PubMed Web of Science ®Google Scholar
• MontiSKlersyCGorlaRFactors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN RegistryClin Rheumatol201736475376128058538
   PubMed Web of Science ®Google Scholar
• BurmesterGRRigbyWFvan VollenhovenRFTocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trialAnn Rheum Dis20167561081109126511996
   PubMed Web of Science ®Google Scholar
• BurmesterGRRigbyWFvan VollenhovenRFTocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trialAnn Rheum Dis20177671279128428389552
   PubMed Web of Science ®Google Scholar
• BijlsmaJWJWelsingPMJWoodworthTGEarly rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trialLancet20163881004234335527287832
   PubMed Web of Science ®Google Scholar
• FavalliEGBiggioggeroMMeroniPLMethotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug?Autoimmun Rev201413111102110825172238
   PubMed Web of Science ®Google Scholar
• FavalliEGBeccioliniABiggioggeroMThe role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registryDrug Des Devel Ther20181214211429
   PubMed Web of Science ®Google Scholar
• KaldenJRSchulze-KoopsHImmunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatmentNat Rev Rheumatol2017131270771829158574
   PubMed Web of Science ®Google Scholar
• EmeryPSebbaAHuizingaTWBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnn Rheum Dis201372121897190423918035
   PubMed Web of Science ®Google Scholar
• ChoyEAletahaDBehrensFMonotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritisRheumatology201756568969727550301
   PubMed Web of Science ®Google Scholar
• JonesGWallaceTMcintoshMJBrockwellLGómez-ReinoJJSebbaAFive-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate- and biologic-naive or free of methotrexate for 6 months: the AMBITION StudyJ Rheumatol201744214214627909081
   PubMed Web of Science ®Google Scholar
• DougadosMKisselKConaghanPGClinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY studyAnn Rheum Dis201473580380924473673
   PubMed Web of Science ®Google Scholar
• ChoyECaporaliRXavierRSubcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countriesRheumatology2018576112929635639
   PubMed Web of Science ®Google Scholar
• O’MahonyAJohnMRChoHHashizumeMChoyEHDiscriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexateJ Transl Med201816115629879987
   PubMed Web of Science ®Google Scholar
• KirwanJRHewlettSEHeibergTIncorporating the patient perspective into outcome assessment in rheumatoid arthritis – progress at OMERACT 7J Rheumatol200532112250225616265712
   PubMedGoogle Scholar
• CrottiCBiggioggeroMBeccioliniAFavalliEGSarilumab: patient-reported outcomes in rheumatoid arthritisPatient Relat Outcome Meas2018927528430154675
   PubMed Web of Science ®Google Scholar
• StrandVMichalskaMBirchwoodCImpact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trialsRMD Open201732e00049628955499
   PubMed Web of Science ®Google Scholar
• StrandVMichalskaMBirchwoodCImpact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritisRMD Open201841e00060229955380
   PubMed Web of Science ®Google Scholar
• BurmesterGRFeistEKellnerHBraunJIking-KonertCRubbert-RothAEffectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)Ann Rheum Dis201170575575921187298
   PubMed Web of Science ®Google Scholar
• IsaacsJDHarariOKoboldULeeJSBernasconiCEffect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritisArthritis Res Ther2013156R20424295403
   PubMed Web of Science ®Google Scholar
• PaulSKMontvidaOBestJHGaleSPethoe-SchrammASarsourKEffectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world dataSemin Arthritis Rheum201847447848428947313
   PubMed Web of Science ®Google Scholar
• SinghJABegSLopez-OlivoMATocilizumab for rheumatoid arthritisCochrane Database Syst Rev20107CD008331
   Google Scholar
• ChoyESattarNInterpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actionsAnn Rheum Dis200968446046919286905
   PubMed Web of Science ®Google Scholar
• NishimotoNItoKTakagiNSafety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensionsMod Rheumatol201020322223220221663
   PubMed Web of Science ®Google Scholar
• RaoVUPavlovAKlearmanMAn evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapyArthritis Rheumatol201567237238025332171
   PubMed Web of Science ®Google Scholar
• GilesJTSattarNGabrielSEComparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trialArthritis Rheumatol201668Suppl 1043574359
   Google Scholar
• GeneraliECarraraGSelmiCComparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanerceptClin Exp Rheumatol201836231031329303702
   PubMed Web of Science ®Google Scholar
• KimSCSolomonDHRogersJRCardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort studyArthritis Rheumatol20176961154116428245350
   PubMed Web of Science ®Google Scholar
• KimSCSolomonDHRogersJRNo difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort studySemin Arthritis Rheum2018 Epub3222018
   Web of Science ®Google Scholar
• WuRLiuXYinJIL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in miceMetabolism201883182429336982
   PubMed Web of Science ®Google Scholar
• ChenDYChenYMHsiehTYHsiehCWLinCCLanJLSignificant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritisArthritis Res Ther2015175225889426
   PubMed Web of Science ®Google Scholar
• SchultzOOberhauserFSaechJEffects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseasesPLoS One2010512e1432821179199
   PubMed Web of Science ®Google Scholar
• BurmesterGRRubbert-RothACantagrelAEfficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Ann Rheum Dis2016751687426056119
   PubMed Web of Science ®Google Scholar
• GenoveseMCRubbert-RothASmolenJSLongterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposureJ Rheumatol201340676878023457383
   PubMed Web of Science ®Google Scholar
• Rubbert-RothASebbaABrockwellLMalignancy rates in patients with rheumatoid arthritis treated with tocilizumabRMD Open201621e00021327252893
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev20112CD008794
   PubMed Web of Science ®Google Scholar
• EspinozaFLe BlayPCombeBBiologic disease-modifying anti-rheumatic drug (bDMARD)-induced neutropenia: a registry from a retrospective cohort of patients with rheumatic diseases treated with 3 classes of intravenous bDMARDJ Rheumatol201744684484928412711
   PubMed Web of Science ®Google Scholar
• StrangfeldARichterASiegmundBRisk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocili-zumab in comparison to treatment with other biologic or conventional synthetic DMARDsAnn Rheum Dis201776350451027405509
   PubMed Web of Science ®Google Scholar
• XieFYunHBernatskySCurtisJRBrief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatmentsArthritis Rheumatol201668112612261727213279
   PubMed Web of Science ®Google Scholar
• MonemiSBerberESarsourKIncidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sourcesRheumatol Ther20163233735227747579
   PubMedGoogle Scholar